# Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors

> **NCT02150408** · NA · COMPLETED · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 35 (actual)

## Conditions studied

- Gastro-Entero-Pancreatic Tumors (GEPs)

## Interventions

- **OTHER:** PET-CT

## Key facts

- **NCT ID:** NCT02150408
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-22
- **Primary completion:** 2017-05-24
- **Final completion:** 2023-04-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02150408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02150408, "Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02150408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*